Last reviewed · How we verify
HepA
HepA, marketed by China National Biotec Group Company Limited, is an established product in the hepatitis A vaccine market. The key composition patent for HepA is set to expire in 2028, providing a period of exclusivity that supports its market position. The primary risk to HepA is the potential increase in competition following the patent expiry in 2028.
At a glance
| Generic name | HepA |
|---|---|
| Sponsor | China National Biotec Group Company Limited |
| Modality | Biologic |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Clean Air for Everyone (CLAIRE): an Intervention Study to Reduce the Amount of Fine Particulate Matter and Microorganisms in Classroom Air (NA)
- Home Air Purification for Eosinophilic COPD (NA)
- Clean Air for Rare MUcociliary Clearance dIsorders (NA)
- The PURI-HF (Air Purifiers on Heart Failure) Trial (NA)
- Cost Effective Air Filtration Intervention in Low-Income Housing to Reduce Asthma Morbidity (NA)
- Booster Dose of sIPV Co-administered With MMR and HepA-I. (PHASE4)
- Reducing Particulate Matter-associated Cardiovascular Health Effects for Seniors (NA)
- the Five-year Antibody Persistence After Immunization With IPV, MMR and HepA-L Vaccines
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- HepA CI brief — competitive landscape report
- HepA updates RSS · CI watch RSS
- China National Biotec Group Company Limited portfolio CI